Prophecys expertise area covers products, services, latest trends, developments, market growth factors, and challenges along with market forecasts in various business areas such as Healthcare, Pharmaceutical, Biotechnology, Information Technology (IT), Automotive, Industrial, Chemical, Agriculture, Food and Beverage, Energy, and Oil and Gas
SURPASS-CN-MONO is a randomized, double-blind, placebo-controlled phase III study designed to evaluate the efficacy and safety of tirzepatide monotherapy compared to placebo in people with type 2 diabetes
Individual clones containing LacAnc100 and LaccID were inoculated into 50 l of SC minimal medium containing 6.7 g l 1 yeast nitrogen base (BD, 291940), 1.92 g l 1 yeast synthetic dropout medium supplement without uracil (Merck, Y1501), 20 g l 1 d-raffinose (Merck, R0250) and 25 g ml 1 chloramphenicol (Merck, C0378) in a sterile 96-well plate (Enzyscreen, CR1496c)
There are probably 100 medications in the pipeline